Relationship between Biodistribution and Tracer Kinetics of <sup>11</sup>C-Erlotinib, <sup>18</sup>F-Afatinib and <sup>11</sup>C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients
Background: Patients with non-small cell lung cancer (NSCLC) driven by activating epidermal growth factor receptor (EGFR) mutations are best treated with therapies targeting EGFR, i.e., tyrosine kinase inhibitors (TKI). Radiolabeled EGFR-TKI and PET have been investigated to study EGFR-TKI kinetics...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/12/4/883 |
| _version_ | 1797436061886971904 |
|---|---|
| author | Eveline Annette van de Stadt Maqsood Yaqub Robert C. Schuit Imke H. Bartelink Anke F. Leeuwerik Lothar A. Schwarte Adrianus J. de Langen Harry Hendrikse Idris Bahce |
| author_facet | Eveline Annette van de Stadt Maqsood Yaqub Robert C. Schuit Imke H. Bartelink Anke F. Leeuwerik Lothar A. Schwarte Adrianus J. de Langen Harry Hendrikse Idris Bahce |
| author_sort | Eveline Annette van de Stadt |
| collection | DOAJ |
| description | Background: Patients with non-small cell lung cancer (NSCLC) driven by activating epidermal growth factor receptor (EGFR) mutations are best treated with therapies targeting EGFR, i.e., tyrosine kinase inhibitors (TKI). Radiolabeled EGFR-TKI and PET have been investigated to study EGFR-TKI kinetics and its potential role as biomarker of response in NSCLC patients with EGFR mutations (EGFRm). In this study we aimed to compare the biodistribution and kinetics of three different EGFR-TKI, i.e., <sup>11</sup>C-erlotinib, <sup>18</sup>F-afatinib and <sup>11</sup>C-osimertinib. Methods: Data of three prospective studies and 1 ongoing study were re-analysed; data from thirteen patients (EGFRm) were included for <sup>11</sup>C-erlotinib, seven patients for <sup>18</sup>F-afatinib (EGFRm and EGFR wild type) and four patients for <sup>11</sup>C-osimertinib (EGFRm). From dynamic and static scans, SUV and tumor-to-blood (TBR) values were derived for tumor, lung, spleen, liver, vertebra and, if possible, brain tissue. AUC values were calculated using dynamic time-activity-curves. Parent fraction, plasma-to-blood ratio and SUV values were derived from arterial blood data. Tumor-to-lung contrast was calculated, as well as (background) noise to assess image quality. Results: <sup>11</sup>C-osimertinib showed the highest SUV and TBR (AUC) values in nearly all tissues. Spleen uptake was notably high for <sup>11</sup>C-osimertinib and to a lesser extent for <sup>18</sup>F-afatinib. For EGFRm, <sup>11</sup>C-erlotinib and <sup>18</sup>F-afatinib demonstrated the highest tumor-to-lung contrast, compared to an inverse contrast observed for <sup>11</sup>C-osimertinib. Tumor-to-lung contrast and spleen uptake of the three TKI ranked accordingly to the expected lysosomal sequestration. Conclusion: Comparison of biodistribution and tracer kinetics showed that <sup>11</sup>C-erlotinib and <sup>18</sup>F-afatinib demonstrated the highest tumor-to-background contrast in EGFRm positive tumors. Image quality, based on contrast and noise analysis, was superior for <sup>11</sup>C-erlotinib and <sup>18</sup>F-afatinib (EGFRm) scans compared to <sup>11</sup>C-osimertinib and <sup>18</sup>F-afatinib (EGFR wild type) scans. |
| first_indexed | 2024-03-09T10:57:15Z |
| format | Article |
| id | doaj.art-64b638caa8ad4002ad214b3cb07f37f1 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-09T10:57:15Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-64b638caa8ad4002ad214b3cb07f37f12023-12-01T01:32:26ZengMDPI AGDiagnostics2075-44182022-04-0112488310.3390/diagnostics12040883Relationship between Biodistribution and Tracer Kinetics of <sup>11</sup>C-Erlotinib, <sup>18</sup>F-Afatinib and <sup>11</sup>C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer PatientsEveline Annette van de Stadt0Maqsood Yaqub1Robert C. Schuit2Imke H. Bartelink3Anke F. Leeuwerik4Lothar A. Schwarte5Adrianus J. de Langen6Harry Hendrikse7Idris Bahce8Department of Pulmonology, Amsterdam UMC Location VUmc, 1081 HV Amsterdam, The NetherlandsDepartment of Radiology and Nuclear Medicine, Amsterdam UMC Location VUmc, 1081 HZ Amsterdam, The NetherlandsDepartment of Radiology and Nuclear Medicine, Amsterdam UMC Location VUmc, 1081 HZ Amsterdam, The NetherlandsDepartment of Clinical Pharmacology and Pharmacy, Amsterdam UMC Location VUmc, 1081 HZ Amsterdam, The NetherlandsDepartment of Clinical Pharmacology and Pharmacy, Amsterdam UMC Location VUmc, 1081 HZ Amsterdam, The NetherlandsDepartment of Anesthesiology, Amsterdam UMC Location VUmc, 1081 HZ Amsterdam, The NetherlandsDepartment of Thoracic Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, The NetherlandsDepartment of Radiology and Nuclear Medicine, Amsterdam UMC Location VUmc, 1081 HZ Amsterdam, The NetherlandsDepartment of Pulmonology, Amsterdam UMC Location VUmc, 1081 HV Amsterdam, The NetherlandsBackground: Patients with non-small cell lung cancer (NSCLC) driven by activating epidermal growth factor receptor (EGFR) mutations are best treated with therapies targeting EGFR, i.e., tyrosine kinase inhibitors (TKI). Radiolabeled EGFR-TKI and PET have been investigated to study EGFR-TKI kinetics and its potential role as biomarker of response in NSCLC patients with EGFR mutations (EGFRm). In this study we aimed to compare the biodistribution and kinetics of three different EGFR-TKI, i.e., <sup>11</sup>C-erlotinib, <sup>18</sup>F-afatinib and <sup>11</sup>C-osimertinib. Methods: Data of three prospective studies and 1 ongoing study were re-analysed; data from thirteen patients (EGFRm) were included for <sup>11</sup>C-erlotinib, seven patients for <sup>18</sup>F-afatinib (EGFRm and EGFR wild type) and four patients for <sup>11</sup>C-osimertinib (EGFRm). From dynamic and static scans, SUV and tumor-to-blood (TBR) values were derived for tumor, lung, spleen, liver, vertebra and, if possible, brain tissue. AUC values were calculated using dynamic time-activity-curves. Parent fraction, plasma-to-blood ratio and SUV values were derived from arterial blood data. Tumor-to-lung contrast was calculated, as well as (background) noise to assess image quality. Results: <sup>11</sup>C-osimertinib showed the highest SUV and TBR (AUC) values in nearly all tissues. Spleen uptake was notably high for <sup>11</sup>C-osimertinib and to a lesser extent for <sup>18</sup>F-afatinib. For EGFRm, <sup>11</sup>C-erlotinib and <sup>18</sup>F-afatinib demonstrated the highest tumor-to-lung contrast, compared to an inverse contrast observed for <sup>11</sup>C-osimertinib. Tumor-to-lung contrast and spleen uptake of the three TKI ranked accordingly to the expected lysosomal sequestration. Conclusion: Comparison of biodistribution and tracer kinetics showed that <sup>11</sup>C-erlotinib and <sup>18</sup>F-afatinib demonstrated the highest tumor-to-background contrast in EGFRm positive tumors. Image quality, based on contrast and noise analysis, was superior for <sup>11</sup>C-erlotinib and <sup>18</sup>F-afatinib (EGFRm) scans compared to <sup>11</sup>C-osimertinib and <sup>18</sup>F-afatinib (EGFR wild type) scans.https://www.mdpi.com/2075-4418/12/4/883non-small cell lung cancerEGFR TKI PET/CTbiodistribution<sup>11</sup>C-erlotinib<sup>18</sup>F-afatinib<sup>11</sup>C-osimertinib |
| spellingShingle | Eveline Annette van de Stadt Maqsood Yaqub Robert C. Schuit Imke H. Bartelink Anke F. Leeuwerik Lothar A. Schwarte Adrianus J. de Langen Harry Hendrikse Idris Bahce Relationship between Biodistribution and Tracer Kinetics of <sup>11</sup>C-Erlotinib, <sup>18</sup>F-Afatinib and <sup>11</sup>C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients Diagnostics non-small cell lung cancer EGFR TKI PET/CT biodistribution <sup>11</sup>C-erlotinib <sup>18</sup>F-afatinib <sup>11</sup>C-osimertinib |
| title | Relationship between Biodistribution and Tracer Kinetics of <sup>11</sup>C-Erlotinib, <sup>18</sup>F-Afatinib and <sup>11</sup>C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients |
| title_full | Relationship between Biodistribution and Tracer Kinetics of <sup>11</sup>C-Erlotinib, <sup>18</sup>F-Afatinib and <sup>11</sup>C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients |
| title_fullStr | Relationship between Biodistribution and Tracer Kinetics of <sup>11</sup>C-Erlotinib, <sup>18</sup>F-Afatinib and <sup>11</sup>C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients |
| title_full_unstemmed | Relationship between Biodistribution and Tracer Kinetics of <sup>11</sup>C-Erlotinib, <sup>18</sup>F-Afatinib and <sup>11</sup>C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients |
| title_short | Relationship between Biodistribution and Tracer Kinetics of <sup>11</sup>C-Erlotinib, <sup>18</sup>F-Afatinib and <sup>11</sup>C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients |
| title_sort | relationship between biodistribution and tracer kinetics of sup 11 sup c erlotinib sup 18 sup f afatinib and sup 11 sup c osimertinib and image quality evaluation using pharmacokinetic pharmacodynamic analysis in advanced stage non small cell lung cancer patients |
| topic | non-small cell lung cancer EGFR TKI PET/CT biodistribution <sup>11</sup>C-erlotinib <sup>18</sup>F-afatinib <sup>11</sup>C-osimertinib |
| url | https://www.mdpi.com/2075-4418/12/4/883 |
| work_keys_str_mv | AT evelineannettevandestadt relationshipbetweenbiodistributionandtracerkineticsofsup11supcerlotinibsup18supfafatinibandsup11supcosimertinibandimagequalityevaluationusingpharmacokineticpharmacodynamicanalysisinadvancedstagenonsmallcelllungcancerpatients AT maqsoodyaqub relationshipbetweenbiodistributionandtracerkineticsofsup11supcerlotinibsup18supfafatinibandsup11supcosimertinibandimagequalityevaluationusingpharmacokineticpharmacodynamicanalysisinadvancedstagenonsmallcelllungcancerpatients AT robertcschuit relationshipbetweenbiodistributionandtracerkineticsofsup11supcerlotinibsup18supfafatinibandsup11supcosimertinibandimagequalityevaluationusingpharmacokineticpharmacodynamicanalysisinadvancedstagenonsmallcelllungcancerpatients AT imkehbartelink relationshipbetweenbiodistributionandtracerkineticsofsup11supcerlotinibsup18supfafatinibandsup11supcosimertinibandimagequalityevaluationusingpharmacokineticpharmacodynamicanalysisinadvancedstagenonsmallcelllungcancerpatients AT ankefleeuwerik relationshipbetweenbiodistributionandtracerkineticsofsup11supcerlotinibsup18supfafatinibandsup11supcosimertinibandimagequalityevaluationusingpharmacokineticpharmacodynamicanalysisinadvancedstagenonsmallcelllungcancerpatients AT lotharaschwarte relationshipbetweenbiodistributionandtracerkineticsofsup11supcerlotinibsup18supfafatinibandsup11supcosimertinibandimagequalityevaluationusingpharmacokineticpharmacodynamicanalysisinadvancedstagenonsmallcelllungcancerpatients AT adrianusjdelangen relationshipbetweenbiodistributionandtracerkineticsofsup11supcerlotinibsup18supfafatinibandsup11supcosimertinibandimagequalityevaluationusingpharmacokineticpharmacodynamicanalysisinadvancedstagenonsmallcelllungcancerpatients AT harryhendrikse relationshipbetweenbiodistributionandtracerkineticsofsup11supcerlotinibsup18supfafatinibandsup11supcosimertinibandimagequalityevaluationusingpharmacokineticpharmacodynamicanalysisinadvancedstagenonsmallcelllungcancerpatients AT idrisbahce relationshipbetweenbiodistributionandtracerkineticsofsup11supcerlotinibsup18supfafatinibandsup11supcosimertinibandimagequalityevaluationusingpharmacokineticpharmacodynamicanalysisinadvancedstagenonsmallcelllungcancerpatients |